Close Menu

Next-Generation Sequencing

The latest news on next-generation sequencing.

The French cancer center will use OncoDNA's blood-based next-generation sequencing test, OncoFollow, in its ongoing SCANDARE study.

At the annual meeting, researchers demonstrated how the growing real-world database can be useful in answering myriad research questions.

In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase. 

The two firms will use their sequencing and informatics technologies to develop personalized cancer vaccines targeting patients' unique neoantigens.

A recent study suggests the lack of diversity in public databases may affect the accuracy of TMB scores and lead to inappropriate treatment for racial minorities.

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.

Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.

The group is setting aside 5 percent of its annual test volume for the underserved and is hoping to partner with pharma and other groups to grow the program.

The rate at which NGS-based algorithms generate obsolete trial matches is a system-wide information shortcoming, not a reflection of the tests themselves.